ERBB2 and breast carcinoma: Here, we took advantage of the JIMT-1 cell line, a unique model of highly-aggressive basal-like/HER2-positive breast cancer naturally overexpressing the immunosuppressive molecule PD-L1 with 100% of the cells positive for PD-L1 [40], to explore the potential regulatory effects of mechanistically diverse metabolism-targeting drugs on PD-L1.